Information Provided By:
Fly News Breaks for June 16, 2015
RDHL
Jun 16, 2015 | 09:00 EDT
After RedHill announced data for its H-pylori treatment, RHB-105, Roth Capital believes there is a 75% chance that the drug will be approved, up from its previous view of 50%. The firm keeps a Buy rating on the stock.
News For RDHL From the Last 2 Days
There are no results for your query RDHL